We’re nonetheless speaking about huge pharma offers and biotech fundraising on this episode. The large information this week was Parabilis Medicines’s history-making IPO. We dive into the drug developer’s plans for the eye-popping $770.5 million that it raised. Subsequent, we talk about the small print of a collaboration between Merck and Protillion Biosciences to make use of synthetic intelligence to find a number of therapeutic candidates. Turning to some newly revealed analysis, we talk about the early outcomes of a first-in-human medical trial that’s testing a twin vaccine towards Lassa fever and rabies, a CRISPR system engineered to selectively set off most cancers cell loss of life by chromatin shredding, and a novel mRNA supply platform for delivering gene therapies beginning with Duchenne muscular dystrophy.
Listed under are hyperlinks to the GEN tales referenced on this episode of Touching Base:
StockWatch: Parabilis Medicines Makes Wall Avenue Historical past with $770.5M IPOBy Alex Philippidis, GEN Edge, June 14, 2026
Merck, Protillion Launch AI Drug Discovery Collaboration with Up-to-$510M in Milestone PaymentsBy Alex Philippidis, GEN Edge, June 16, 2026
First-in-Human Trial Reviews Promising Twin Lassa–Rabies Vaccine DataGEN, June 9, 2026
CRISPR Shreds Undruggable Most cancers Cells with PrecisionBy Fay Lin, PhD, GEN Edge, June 8, 2026
New mRNA Supply Platform Restores Muscle Operate in DMD ModelsGEN, June 11, 2026
Touching Base PodcastHosted by Corinna Singleman, PhD
Behind the BreakthroughsHosted by Jonathan D. Grinstein, PhD
